Stonepine Capital Management LLC Sells 1,016,745 Shares of Evolus, Inc. (NASDAQ:EOLS)

Stonepine Capital Management LLC decreased its position in Evolus, Inc. (NASDAQ:EOLS) by 38.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,657,611 shares of the company’s stock after selling 1,016,745 shares during the quarter. Evolus comprises approximately 16.4% of Stonepine Capital Management LLC’s holdings, making the stock its 3rd largest position. Stonepine Capital Management LLC owned approximately 2.65% of Evolus worth $17,985,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Quest Partners LLC bought a new stake in Evolus in the second quarter worth about $43,000. Quarry LP bought a new stake in shares of Evolus in the 2nd quarter worth approximately $54,000. Sierra Summit Advisors LLC acquired a new stake in Evolus during the fourth quarter valued at approximately $119,000. Profund Advisors LLC bought a new stake in Evolus during the second quarter worth approximately $130,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Evolus by 65.8% in the first quarter. China Universal Asset Management Co. Ltd. now owns 10,969 shares of the company’s stock worth $154,000 after buying an additional 4,355 shares during the last quarter. Institutional investors own 90.69% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EOLS. Cantor Fitzgerald reiterated an “overweight” rating on shares of Evolus in a research report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research report on Thursday, August 1st. Barclays lifted their price target on Evolus from $16.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, September 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Friday, September 13th.

Insider Activity

In related news, CFO Sandra Beaver sold 3,276 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $14.98, for a total transaction of $49,074.48. Following the completion of the sale, the chief financial officer now directly owns 148,502 shares in the company, valued at $2,224,559.96. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In related news, CFO Sandra Beaver sold 3,276 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $14.98, for a total value of $49,074.48. Following the completion of the sale, the chief financial officer now owns 148,502 shares of the company’s stock, valued at approximately $2,224,559.96. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,631 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $15.85, for a total transaction of $89,251.35. Following the transaction, the chief marketing officer now directly owns 82,375 shares in the company, valued at approximately $1,305,643.75. The disclosure for this sale can be found here. 6.10% of the stock is currently owned by corporate insiders.

Evolus Trading Up 1.6 %

Shares of NASDAQ EOLS opened at $16.20 on Tuesday. The company has a current ratio of 2.92, a quick ratio of 2.67 and a debt-to-equity ratio of 6.26. Evolus, Inc. has a one year low of $7.44 and a one year high of $17.70. The business has a 50-day moving average price of $14.76 and a two-hundred day moving average price of $13.19. The firm has a market capitalization of $1.01 billion, a PE ratio of -15.43 and a beta of 1.31.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Wednesday, July 31st. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). The company had revenue of $66.91 million for the quarter, compared to analyst estimates of $65.06 million. As a group, analysts predict that Evolus, Inc. will post -0.64 earnings per share for the current fiscal year.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.